Search in:

Advanced search

Expert Opinion on Emerging Drugs Volume 13, 2008 - Issue 4

Submit an article Journal homepage

450

Views

CrossRef citations to date

Altmetric

Review

Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes

Bo Ahrén Lund University, Department of Clinical Sciences, Division of Medicine, BMC B11, SE-221 84, Lund, Sweden +46 46 2220758; [email protected]

Pages 593-607 | Published online: 02 Dec 2008

Cite this article
https://doi.org/10.1517/14728210802584126

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Mentlein R. Dipeptidyl-peptidase IV (CD26) – role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24
PubMed Web of Science ®Google Scholar
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
PubMed Web of Science ®Google Scholar
Ahrén B. Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. Bioessays 1998;20:642-51
PubMed Web of Science ®Google Scholar
Dunning BE, Foley JE, Ahrén B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005;48:1700-13
PubMed Web of Science ®Google Scholar
Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res 2004;36:804-10
PubMed Web of Science ®Google Scholar
Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-5
PubMed Web of Science ®Google Scholar
Nyström T, Gutniak M, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol 2004;287:E1209-15
PubMedGoogle Scholar
Ahrén B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab 2007;21:517-33
PubMed Web of Science ®Google Scholar
Ahrén B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care 2007;30:1344-50
PubMed Web of Science ®Google Scholar
Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl-5, 6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:141-51
PubMed Web of Science ®Google Scholar
Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003;46:2774-89
PubMed Web of Science ®Google Scholar
Ahrén B. Vildagliptin: novel pharmacological approach to treat type 2 diabetes. Therapy 2008;5:79-90
Google Scholar
Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2006;48:5025-37
Web of Science ®Google Scholar
Deacon CF. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Curr Opin Invest Drugs 2008;9:402-13
PubMed Web of Science ®Google Scholar
Bergman AJ, Coyte J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a selective dipeptidyl-peptidase-4 inhibitor. Diabetes Care 2007;30:1862-4
PubMed Web of Science ®Google Scholar
Fonseca V. Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. Curr Med Res Opin 2003;19:635-41
PubMed Web of Science ®Google Scholar
Lehy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res 2005;36:197-209
PubMed Web of Science ®Google Scholar
Wajchenberg BL. β-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218
PubMed Web of Science ®Google Scholar
Inzucchi S. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002;287:360-72
PubMed Web of Science ®Google Scholar
Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 2001;358:739-46
PubMed Web of Science ®Google Scholar
Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-21
PubMed Web of Science ®Google Scholar
Hsia SH, Davidson MB. Established therapies for diabetes mellitus. Curr Med Res Opin 2002;18(suppl 1):S13-21
Google Scholar
Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004;64:1339-58
PubMed Web of Science ®Google Scholar
Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003;63:1373-405
PubMed Web of Science ®Google Scholar
Hussein Z, Wentworth JM, Nankervis AJ, et al. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. Med J Austr 2004;181:536-9
PubMed Web of Science ®Google Scholar
Bailey CJ. Drugs on the horizon for diabesity. Curr Diab Rep 2005;5:353-9
PubMedGoogle Scholar
Ahrén B. Exenatide: a novel treatment of type 2 diabetes. Therapy 2005;2:207-22
Google Scholar
Ahrén B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078-84
PubMed Web of Science ®Google Scholar
Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4888-94
PubMed Web of Science ®Google Scholar
Ahrén B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936-40
PubMed Web of Science ®Google Scholar
Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-71
PubMed Web of Science ®Google Scholar
Ahrén B, Pacini G, Tura A, et al. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Horm Metab Res 2007;39:826-9
PubMed Web of Science ®Google Scholar
Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007;92:1249-55
PubMed Web of Science ®Google Scholar
Ahrén B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4 week study period in type 2 diabetes. Diabetes Care 2002;25:869-75
PubMed Web of Science ®Google Scholar
Brazg R, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabet Obes Metab 2007;9:186-93
PubMed Web of Science ®Google Scholar
Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006;55:1695-704
PubMed Web of Science ®Google Scholar
Ahrén B, Sörhede Winzell M, Wierup N, et al. DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell specific overexpression of human islet amyloid polypeptide. Regul Pept 2007;143:97-103
PubMed Web of Science ®Google Scholar
Azuma K, Radikova Z, Mancino JM, et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:459-64
PubMed Web of Science ®Google Scholar
Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabet Obes Metab 2005;7:692-8
PubMed Web of Science ®Google Scholar
Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006;387:423-38
Web of Science ®Google Scholar
Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76;132-8
PubMed Web of Science ®Google Scholar
Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24 week double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007;39:218-23
PubMed Web of Science ®Google Scholar
Scherbaum WA, Schweizer A, Mari A, et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabet Obes Metab 2008; In press
Google Scholar
Rosenstock J, Foley JE, Rendell M, et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008;31:30-5
PubMed Web of Science ®Google Scholar
Hanefeld M, Herman GA, Wu M, et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007;23:1329-39
PubMed Web of Science ®Google Scholar
Scott R, Wu L, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007;61:171-80
PubMed Web of Science ®Google Scholar
Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7
PubMed Web of Science ®Google Scholar
Qi DS, Teng R, Jiang M, et al. Two-year treatment with sitagliptin and initial combination therapy of sitagliptin and metformin provides substantial and durable glycaemic control in patients with type 2 diabetes. Diabetologia 2008;51(Suppl 1):S36
Google Scholar
Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. Diabet Obes Metab 2008;10:376-86
PubMed Web of Science ®Google Scholar
Rosenstock J, Aguilar-Salinas CA, Klein E, et al. Once-daily saxagliptin monotherapy improves glycemic control in drug-naïve patients with type 2 diabetes. Diabetes 2008;57(Suppl 1):A154
Google Scholar
Chen R, Pfützner A, Jadzinsky M, et al. Initial combination therapy with saxagliptin and metformin improves glycaemic control compared with either monotherapy alone in drug-naïve patients with type 2 diabetes. Diabetologia 2008;51(Suppl 1):S38
Web of Science ®Google Scholar
Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomised, double-blind, placebo-controlled, multiple-dose study in adults patients with type 2 diabetes. Clin Ther 2008;30:499-512
PubMed Web of Science ®Google Scholar
De Fronzo RA, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes mellitus and inadequate glycemic control: a randomized, double-bind, placebo-controlled study. Diabetes Care 2008; In press
Google Scholar
Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naïve elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 2007;30:3017-22
PubMed Web of Science ®Google Scholar
Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007;30:217-23
PubMed Web of Science ®Google Scholar
Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabet Med 2007;24:955-61
PubMed Web of Science ®Google Scholar
Ahrén B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27:2874-80
PubMed Web of Science ®Google Scholar
Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-5
PubMed Web of Science ®Google Scholar
Ferranini E, et al. 52-Week efficacy and safety of vildagliptin versus glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2008; In press
Google Scholar
Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43
PubMed Web of Science ®Google Scholar
Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87
PubMed Web of Science ®Google Scholar
Ellis G, Fleck P, Wilson C, et al. Alogliptin added to metformin therapy in patients with type 2 diabetes reduces HbA1c without changing weight or increasing gastrointestinal symptoms or hypoglycemia. Diabetologia 2008;51(Suppl 1):S343
Google Scholar
Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week randomized, double-blind study. Diabet Obes Metab 2008;10:82-90
PubMed Web of Science ®Google Scholar
Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabet Obes Metab 2007;9:194-205
PubMed Web of Science ®Google Scholar
Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabet Obes Metab 2008;10:959-69
PubMed Web of Science ®Google Scholar
Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabet Obes Metab 2007;9:166-74
PubMed Web of Science ®Google Scholar
Rosenstock J, Brazg RG, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-68
PubMed Web of Science ®Google Scholar
Allen A, Hollander P, Li J, Chen R. Saxagliptin added to a thiazolidinedione improves glycaemic control in patients with inadequately controlled type 2 diabetes. Diabetologia 2008;51(Suppl 1):S342-3
Google Scholar
Pratley R, Reusch J, Fleck P, et al. Alogliptin added to pioglitazone therapy improves glycaemic control in patients with type 2 diabetes without increasing weight gain or hypoglycaemia. Diabetologia 2008;51(Suppl 1):S343
Google Scholar
Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabet Obes Metab 2008; In press
Google Scholar
Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabet Obes Metab 2007;9:733-45
PubMed Web of Science ®Google Scholar
Ravichandran S, Chacra AR, Tan GH, et al. Saxagliptin added to a sulfonylurea is safe and more efficacious than uptitrating a sulfonylurea in patients with type 2 diabetes. Diabetologia 2008;51(Suppl 1):S342
Google Scholar
Fleck P, Mekki Q, Kipnes M, et al. Efficacy and safety of alogliptin and glyburide combination therapy in patients with type 2 diabetes. Diabetologia 2008;51(Suppl 1):S37
Google Scholar
Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycemic control in type 2 diabetes. Diabetologia 2007;50:1148-55
PubMed Web of Science ®Google Scholar
Rendell M, Rosenstock J, Gross J, et al. Addition of alogliptin to insulin therapy reduces HbA1c without increasing weight gain or hypoglycaemia in patients with type 2 diabetes. Diabetologia 2008;51(Suppl 1):S37-8
Google Scholar
Arjona Ferreira JC, Dobs A, Goldstein BJ, et al. Triple combination therapy with sitagliptin, metformin and rosiglitazone improves glycaemic control in patients with type 2 diabetes. Diabetologia 2008;51(Suppl 1): S365
PubMed Web of Science ®Google Scholar
Matikainen N, Mänttäri S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006;49:2049-57
PubMed Web of Science ®Google Scholar
Bosi E, Byiers SR, Cohen SE. Vildagliptin significantly decreases blood pressure in hypertensive patients with type 2 diabetes compared with metformin. Diabetes 2007;56(Suppl 1):A139
Google Scholar
Kothany W, Gimpelewics C, Byiers S, et al. Cardiovascular safety profile of vildagliptin a new DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetologia 2008;51(Suppl 1):S367
Google Scholar
Williams-Herman D, Round E, Swern A, et al. Safety, tolerability of sitagliptin, a selective DPP-4 inhibitor, in patients with type 2 diabetes: pooled analysis of 6139 patients in clinical trials for up to 2 years. Diabetologia 2008;51(Suppl 1):365-6
PubMed Web of Science ®Google Scholar
Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76:132-8
PubMed Web of Science ®Google Scholar
Göke B, Hershon K, Kerr D, et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes. Comparison with metformin. Horm Metab Res 2008; In press
PubMed Web of Science ®Google Scholar
Karasik A, Aschner P, Katzeff H, et al. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin 2008;24:489-96
PubMed Web of Science ®Google Scholar
De Heer J, Holst JJ. Sulphonylurea compounds uncouple the glucose dependence of the insulionotropic effect of glucagon-like peptide 1. Diabetes 2007;56:438-43
PubMed Web of Science ®Google Scholar
Ahrén B, Schweizer A, Dejager S, et al. Vildagliptin suppresses prandial glucagon but enhances the glucagon response to hypoglycemia. Diabetes 2008;57(Suppl 1):A166-7
Google Scholar
Ahrén B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004;36:867-76
PubMed Web of Science ®Google Scholar
Novartis AG. New Galvus clinical data reinforces efficacy profile; safety update provided to regulatory agencies. Press Release, 6 Nov 2007
Google Scholar
Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabet Obes Metab 2008;10:545-55
PubMed Web of Science ®Google Scholar
Thuren T, Bryiers S, Mohideen P, Goodman M. Vildagliptin is safe and well tolerated in patients with mild or moderate renal impairment. Diabetologia 2008;51(Suppl 1):S36
Google Scholar
Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54:2988-94
PubMed Web of Science ®Google Scholar
Burkey BF, Hoffmann PK, Hassiepen U, et al. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabet Obes Metab 2008; In press
PubMed Web of Science ®Google Scholar
Ahrén B, Foley JE. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Int J Clin Pract 2008;62(Suppl 159):8-14
PubMed Web of Science ®Google Scholar
Migoya EM, Miller JL, Larson PJ, et al. Sitagliptin, a selective DPP-4 inhibitor and metformin have complimentary effects to increase active GLP-1 concentrration. Diabetologia 2007;50(Suppl 1):S52
Google Scholar
Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24:489-94
PubMed Web of Science ®Google Scholar
Green BD, Duffy NA, Irwin N, et al. Inhibition of dipeptidyl peptidase-IV (DPP IV) activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1 (GLP-1). Eur J Pharmacol 2006;547:192-9
PubMed Web of Science ®Google Scholar
Lenhard JM, Croom DK, Minnick DT. Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem Biophys Res Commun 2004;324:92-7
PubMed Web of Science ®Google Scholar
Lindsay JR, Duffy NA, Mckillop AM, et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med 2005;22:654-7
PubMed Web of Science ®Google Scholar
Madsen K, et al. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J Med Chem 2007;50:6126-32
PubMed Web of Science ®Google Scholar
Matthews JE, et al. Pharmacodynamics, pharmacokinetics, safety and tolerability of albiglutide, a long-acting GLP-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; In press
Google Scholar
Berria R, et al. 8 weeks treatment with R1583, a novel long-acting, human GLP-1 analogue improves beta cell function in metformin-treated diabetic subjects: a double-blind, placebo-controlled phase 2 study. Diabetologia 2008;51(Suppl 1):S347-8
PubMed Web of Science ®Google Scholar
Baggio LL, et al. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 2008;134:1137-47
PubMed Web of Science ®Google Scholar
Werner U. Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010. Ann Endocrinol 2008;69:164-5
PubMed Web of Science ®Google Scholar
Carr RD, Larsen MO, Winzell MS, et al. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Am J Physiol 2008;295:E779-84
PubMedGoogle Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date